<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732146</url>
  </required_header>
  <id_info>
    <org_study_id>110111</org_study_id>
    <nct_id>NCT01732146</nct_id>
  </id_info>
  <brief_title>Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy</brief_title>
  <acronym>Neurepo</acronym>
  <official_title>Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of high dose Erythropoietin to improve
      survival and neurologic outcome in asphyxiated term newborn undergoing cooling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic-ischemic encephalopathy remains the main cause of death or long term neurologic
      impairments in neonates. Yet, therapies for birth asphyxia are currently limited. Hypothermia
      when applied within 6 hours after birth demonstrate partial improvement in outcome of
      newborns specially those with moderate form. Erythropoietin and its receptors are upregulated
      after brain injury in ischemic conditions. Systemically administered erythropoietin is
      neuroprotective in animal models of birth asphyxia. To date, one study demonstrate
      improvement neurologic outcome in asphyxiated term newborn under erythropoietin treatment but
      no reports evaluating beneficial of erythropoietin associated with cooling. This is a large
      randomised controlled trial to evaluate the efficacy of high dose erythropoietin on outcome
      at two years of asphyxiated term newborns undergoing cooling.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without neurologic sequelae</measure>
    <time_frame>at 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>Within 24 months</time_frame>
    <description>number of dead patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of moderate and severe sequelae</measure>
    <time_frame>at 24 months</time_frame>
    <description>Mental Developmental index (Brunet Lezine Test), motor, visual and hearing impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspect of brain lesions on MRI</measure>
    <time_frame>at day 6 and day 12 after birth</time_frame>
    <description>Brain MRI performed between day 6 and day 12 after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of treatment</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Erythropoietin beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 to 1500 U/kg/dose X 3 every 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.2 ml saline solution X 3 given every 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin Beta</intervention_name>
    <description>erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery</description>
    <arm_group_label>Erythropoietin beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.2 ml saline solution X 3 given every 24 hours with the first dose within 12 hours of delivery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term or near-term newborn (&gt; = 36 weeks gestational age)

          -  Moderate to severe encephalopathy

          -  undergoing moderate controlled hypothermia started within 6 hours after delivery :
             rectal or esophageal temperature maintained at 33.5 ° C + / - 0.5 ° C before H6

          -  Beneficiary of social security plan

          -  Informed consent parental authority

        Exclusion Criteria:

          -  Impossibility of getting controlled hypothermia before H6

          -  Infant older than 12 hours of age

          -  Chromosomal or significant congenital abnormality

          -  Predictable surgery in the first 3 days of life

          -  Uncontrolled collapse

          -  Haemorrhagic syndrome unchecked

          -  Head trauma with or without skull fracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana Patkai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cochin Hospital, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K, Wang X. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009 Aug;124(2):e218-26. doi: 10.1542/peds.2008-3553. Epub 2009 Jul 27.</citation>
    <PMID>19651565</PMID>
  </reference>
  <reference>
    <citation>Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015 Jan;145:213-25. doi: 10.1016/j.jsbmb.2014.06.003. Epub 2014 Jul 5. Review.</citation>
    <PMID>25008465</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2012</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxic Ischemic Encephalopathy</keyword>
  <keyword>Term neonate</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

